It can inhibit platelet aggregation and prevent thrombosis. It can also counteract vascular damage caused by 5-hydroxytryptamine and bradykinin, increase capillary resistance, reduce capillary permeability, and prevent edema caused by increased vascular permeability.

It can inhibit the synthesis and release of prostaglandin E1 in the neurons of the anterior hypothalamus, restore the normal responsiveness of the receptor neurons in the body temperature regulation center and have an antipyretic effect; it can also inhibit the synthesis and release of prostaglandins in local inflammatory tissues, stabilize the lysosomal membrane, and affect the phagocytic function of macrophages, thereby playing an anti-inflammatory role.

As a central nervous system stimulant, it can excite the cerebral cortex, increase sensitivity to the outside world, constrict cerebral blood vessels, enhance the effect of aminopyrine in relieving headaches, and have a synergistic antipyretic and analgesic effect.

Tetracycline antibiotics. This product is a broad-spectrum antibacterial agent. Many Rickettsia, Mycoplasma, Chlamydia, and Spirochete are sensitive to this product. Enterococci are resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, Yersinia, etc. are also sensitive to this product. There is cross-resistance between this product and different varieties of tetracycline antibiotics. The mechanism of action of this product is that the drug can specifically bind to the A position of the 30S subunit of the bacterial ribosome, inhibit the growth of the peptide chain and affect the synthesis of bacterial proteins.

This product is a non-narcotic antitussive drug that mainly blocks the incoming sensory nerve impulses of the lung and pleural receptors, and also directly inhibits the antitussive center. It also has a papaverine-like smooth muscle spasmolytic effect

It competes with p-aminobenzoic acid for dihydrofolate synthase, hindering bacterial synthesis of dihydrofolate. When used in combination with trimethoprim, it can double block the bacterial tetrahydrofolate synthesis process.

It competes with p-aminobenzoic acid for dihydrofolate synthase, hindering bacterial synthesis of dihydrofolate. When used in combination with trimethoprim, it can double block the bacterial tetrahydrofolate synthesis process.

By inhibiting bacterial dihydrofolate reductase, it hinders the reduction of dihydrofolate to tetrahydrofolate. When used in combination with sulfonamides, it can double block the bacterial tetrahydrofolate synthesis process.